Roche’s Next Front For Innovation: Reimbursement
Roche is preparing for the ripple effects of its burgeoning oncology pipeline by trying to innovate on reimbursement models as well. But indication-based and outcome-based pricing are still “a long ways off,” COO O’Day says.
You may also be interested in...
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.